查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1748749

雙特異性抗體治療合約製造市場－全球產業規模、佔有率、趨勢、機會和預測（按適應症、給藥途徑、最終用途、地區和競爭細分，2020-2030 年預測）

Bispecific Antibody Therapeutics Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Route of Administration, By End Use, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球雙特異性抗體治療合約製造市場規模達73.2億美元，預計2030年將達到187.4億美元，年複合成長率達16.92%。雙特異性抗體因其能夠同時靶向兩種不同抗原的能力，在生物製藥行業備受矚目，為癌症和自體免疫疾病等複雜疾病提供了新的治療策略。合約製造組織 (CMO) 在這一領域發揮著至關重要的作用，它們提供生產這些複雜生物製劑所需的基礎設施、技術專長和可擴展性。快速擴張的雙特異性抗體候選藥物管線，以及許多生物製藥公司傾向於外包的專業化製造能力需求，共同推動市場的發展。隨著企業不斷開發創新的雙特異性抗體形式和治療應用，對靈活、高品質製造支援的需求預計將穩定成長，這將進一步強化CMO在推動下一代生物療法發展中的作用。

市場概覽
預測期 2026-2030
2024年市場規模 73.2億美元
2030年市場規模 187.4億美元
2025-2030 年複合年成長率 16.92%
成長最快的領域 自體發炎與自體免疫疾病
最大的市場 北美洲

關鍵市場促進因素

雙特異性抗體療法的持續研究活動

主要市場挑戰

雙特異性抗體療法生產面臨的挑戰

主要市場趨勢

雙特異性抗體的需求不斷增加

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按適應症（癌症、傳染病、自體發炎和自體免疫疾病、中樞神經系統疾病、其他）
    • 依給藥途徑（靜脈注射、皮下注射、其他）
    • 依最終用途（製藥公司、生物製藥公司、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲雙特異性抗體治療合約製造市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Lonza Group AG
  • Creative Biolabs Inc
  • Amgen Inc
  • Johnson & Johnson
  • Wuxi Biologics Cayman Inc
  • Roche Holding AG
  • Sino Biological Inc
  • IQVIA Inc
  • Janssen Pharmaceuticals Inc
  • AbbVie Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16116

The Global Bispecific Antibody Therapeutics Contract Manufacturing Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 18.74 billion by 2030, growing at a CAGR of 16.92%. Bispecific antibodies have gained significant traction in the biopharmaceutical industry for their ability to target two different antigens simultaneously, offering novel therapeutic strategies for complex diseases such as cancer and autoimmune disorders. Contract manufacturing organizations (CMOs) play a crucial role in this landscape by providing the infrastructure, technical expertise, and scalability required to manufacture these complex biologics. The market is being driven by a rapidly expanding pipeline of bispecific antibody candidates and the need for specialized manufacturing capabilities that many biopharma companies prefer to outsource. As companies continue to develop innovative bispecific formats and therapeutic applications, the demand for flexible, high-quality manufacturing support is expected to rise steadily, reinforcing the role of CMOs in advancing next-generation biologic therapies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.32 Billion
Market Size 2030USD 18.74 Billion
CAGR 2025-203016.92%
Fastest Growing SegmentAutoinflammatory and Autoimmune Diseases
Largest MarketNorth America

Key Market Drivers

Ongoing Research Activities in Bispecific Antibody Therapeutics

The Global Bispecific Antibody Therapeutics Contract Manufacturing Market is experiencing strong growth due to intensifying research and development efforts. As of early 2025, there are more than 200 bispecific antibody candidates in various stages of development, with over 50 undergoing clinical trials targeting oncology, autoimmune conditions, and infectious diseases. The structural diversity of bispecific formats-such as BiTEs, DVD-Igs, and tandem diabodies-requires advanced design and production capabilities. CMOs with expertise in bispecific antibody manufacturing are increasingly in demand as they provide essential services like high-throughput analytics, improved purification processes, and scalable production systems. With more than 60% of biologics-focused CMOs having expanded capabilities tailored to bispecifics, the sector is seeing a surge in specialized offerings aimed at supporting the growing complexity and volume of these novel therapeutics.

Key Market Challenges

Challenges Associated with Manufacturing of Bispecific Antibody Therapeutics

Manufacturing bispecific antibody therapeutics presents a unique set of challenges that differentiate them from traditional monoclonal antibodies. The complexity of these molecules-arising from their dual-target structure-necessitates precise control over manufacturing to ensure consistency and efficacy. Post-translational modifications such as glycosylation and oxidation introduce further heterogeneity, requiring robust analytical oversight. Scale-up remains a critical hurdle, as production must transition smoothly from development to commercial levels without compromising quality. Custom purification strategies are often required due to the distinct molecular properties of each bispecific antibody, complicating downstream processing. Additionally, the need for specialized equipment, such as bioreactors and chromatography systems suited for bispecifics, results in higher capital investment. Regulatory compliance adds another layer of complexity, as evolving global guidelines demand rigorous quality and safety controls, further elevating the operational demands for CMOs in this field.

Key Market Trends

Increasing Demand for Bispecific Antibodies

The rising demand for bispecific antibodies is a dominant trend shaping the Global Bispecific Antibody Therapeutics Contract Manufacturing Market. These molecules offer the ability to engage two targets simultaneously, providing novel mechanisms of action in diseases like cancer, autoimmune disorders, and infections. In oncology, bispecific T-cell engagers (BiTEs) have shown strong therapeutic potential by redirecting immune responses toward cancer cells, prompting further clinical exploration. The trend toward personalized medicine is also driving demand for customizable bispecific formats tailored to specific disease subtypes or patient groups. As biopharmaceutical companies seek contract partners capable of delivering precision-engineered therapeutics at scale, the market for CMOs offering flexible and advanced bispecific antibody manufacturing continues to grow. This rising demand, coupled with innovations in therapeutic design, is positioning bispecific antibodies as a key area of growth within the broader biologics manufacturing ecosystem.

Key Market Players

  • Lonza Group AG
  • Creative Biolabs Inc
  • Amgen Inc
  • Johnson & Johnson
  • Wuxi Biologics Cayman Inc
  • Roche Holding AG
  • Sino Biological Inc
  • IQVIA Inc
  • Janssen Pharmaceuticals Inc
  • AbbVie Inc

Report Scope:

In this report, the Global Bispecific Antibody Therapeutics Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Indication:

  • Cancer
  • Infectious Diseases
  • Autoinflammatory and Autoimmune Diseases
  • CNS Conditions
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Route of Administration:

  • Intravenous
  • Subcutaneous
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By End Use:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibody Therapeutics Contract Manufacturing Market.

Available Customizations:

Global Bispecific Antibody Therapeutics Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customers

5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Cancer, Infectious Diseases, Autoinflammatory and Autoimmune Diseases, CNS Conditions, Others)
    • 5.2.2. By Route of Administration (Intravenous, Subcutaneous, Others)
    • 5.2.3. By End Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indications
    • 6.2.2. By Route of Administration
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indications
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indications
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indications
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End Use

7. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indications
    • 7.2.2. By Route of Administration
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indications
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indications
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indications
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indications
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indications
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End Use

8. Asia-Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indications
    • 8.2.2. By Route of Administration
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indications
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indications
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indications
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indications
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indications
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End Use

9. South America Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indications
    • 9.2.2. By Route of Administration
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indications
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indications
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indications
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End Use

10. Middle East and Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indications
    • 10.2.2. By Route of Administration
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indications
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indications
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE Bispecific Antibody Therapeutics Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indications
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Lonza Group AG
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Product & Services
    • 15.1.4. Financials (In case of listed companies)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Creative Biolabs Inc
  • 15.3. Amgen Inc
  • 15.4. Johnson & Johnson
  • 15.5. Wuxi Biologics Cayman Inc
  • 15.6. Roche Holding AG
  • 15.7. Sino Biological Inc
  • 15.8. IQVIA Inc
  • 15.9. Janssen Pharmaceuticals Inc
  • 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer